AllSci News
Curium clears patent hurdle to challenge Novartis’s lutetium Lu 177 dotatate monopoly
Boston-based Curium Pharma prevailed in a patent dispute brought by Novartis subsidiary Advanced Accelerator Applications (AAA) before the Delaware US District Court,…
NYU investigates long non-coding RNAs as drivers of stress susceptibility and resilience
New York University School of Medicine has received a USD 1.69 million NIH R56 award to investigate the role of long non-coding RNAs in stress...
Jinan University develops light-activated hydrogel system targeting lipid metabolism and postsurgical tumor recurrence
Researchers at Jinan University in Guangzhou, China have reported a thermotropic hydrogel tumor therapy platform that exploits the fatty acid-rich...
Teva files Emalex's ecopipam with US FDA for first approval as Tourette's therapy
Teva Pharmaceutical Industries (NYSE: TEVA) has submitted a New Drug Application (NDA) to the US FDA for ecopipam, an investigational selective dopamine D1...
Scripps wins NCI renewal to study circadian control of HIF2α in kidney cancer
Scripps Research has received a USD 1.39 million NCI R01 renewal to investigate how circadian clock proteins regulate HIF2α activity in clear cell renal...
Mabwell's Nectin-4 ADC challenges Pfizer's Tivdak with 77% response rate in combination study
China-based Mabwell (688062.SH, 02493.HK) reported early-stage clinical data for its Nectin-4-targeting antibody-drug conjugate 9MW2821 (bulumtatug...
UBC researchers suggest semaglutide's skeletal effects reflect weight loss, not GLP-1 activity
Researchers at the University of British Columbia (UBC) in Vancouver, Canada report that semaglutide produces measurable reductions in bone mass and...
Novocure's glioblastoma expansion bid fails, leaving Optune's label unchanged
A Phase III trial failure that leaves Novocure's approved label intact but closes the door on a meaningful expansion opportunity — that is the central...
Chai’s AI miniprotein engine joins Lilly’s TuneLab ecosystem for select biotech partners
San Francisco-based Chai Discovery announced a collaboration with Eli Lilly and Company’s (NYSE: LLY) TuneLab platform that will make Chai’s frontier AI…
Merck’s Capvaxive becomes first PCV approved specifically for high-risk children aged 2-17
Merck (NYSE: MRK) has received US FDA approval for an expanded indication related to Capvaxive (pneumococcal 21-valent conjugate vaccine), extending its use…
Portal's mechanoporation platform scales to 100 pharma and academic sites with USD 9 million round
Watertown, Massachusetts-based Portal Biotechnologies, Inc., a cell engineering and drug discovery platform company, has closed an oversubscribed USD 9...
Nortiva Bio launches with USD 5m Gates Foundation grant for long-acting oral contraceptive
Lexington, Massachusetts-based Nortiva Bio, Inc. has launched as a clinical-stage biopharmaceutical company focused on extending the duration of oral...
Voro and Alloy combine tumor-targeting and T-cell engineering to curb engager toxicity
San Diego-based Voro Therapeutics and Boston-based Alloy Therapeutics have announced a strategic research collaboration to discover and develop next-generation masked T-cell engager…
Takeda deploys Boltz’s biomolecular AI across research organization in platform access deal
Massachusetts-based Boltz PBC and Takeda announced a platform collaboration under which Boltz’s proprietary biomolecular AI models will be deployed across Takeda’s Research…
Scribe takes USD 25m in CIRM funding to push CRISPR CVD programs into clinic
Scribe Therapeutics has received more than USD 25 million from the California Institute for Regenerative Medicine (CIRM) to advance two preclinical...
The AllSci Brief
Free, systematic R&D and deal news. Daily.